ClinicalTrials.gg
RecruitingNCT07662135Eluminate-4Updated Sep 2, 2026

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

A Phase 3 interventional study of Elecoglipron and Placebo in Type 2 Diabetes Mellitus and Type 2 Diabetes With Chronic Kidney Disease, sponsored by AstraZeneca. Recruiting at 186 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 6 of them phase 3. elecoglipron · Diabetes Mellitus, Type 2.

Planned enrollment
3rd of 18
900 · median 57
Started
2026
with 8 others
Phase 3
6 of 18
6 open now
Registered
13th of 18
by date
Lead sponsor
14 of 18
AstraZeneca

Among the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, this one is the 3rd largest by planned enrollment, is one of 9 that started in 2026, is one of 6 in phase 3, and was the 13th registered.

Diabetes Mellitus, Type 2

10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About elecoglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background of sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin 10 mg as per guideline directed medical therapy (GDMT) for chronic kidney disease (CKD). Additionally, participants are on other glucose-lowering medication(s).

03

Conditions studied

  • Type 2 Diabetes Mellitus
  • Type 2 Diabetes With Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Type 2 Diabetes Mellitus for at least 90 days prior to screening
  • On SGTL2i or SGLT2i-naïve and other glucose lowering medication(s)
  • value:

    1. On stable dose of SGLT2i ≥ 7.0 % to ≤ 10.5% (53 to 91.3 mmol/mol)
    2. SGLT2i-naive ≥ 7.5% to ≤ 10.5% (58 to 91.3 mmol/mol)
  • Impaired renal function
  • (BMI) of ≥ 23 kg/m2 at screening
  • Stable body weight (self-reported or documented) for 90 days prior to screening

Exclusion criteria

Exclusion Criteria:

  • Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
  • Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
  • Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
  • condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
  • History of acute or chronic pancreatitis
  • Severe congestive heart failure ( IV)
  • History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
900 participants (estimated)

Study arms

  • Experimental
    Elecoglipron dose level 1

    Participants will receive elecoglipron at dose level 1, administered orally once daily, in addition to background dapagliflozin 10 mg.

    Drug: Elecoglipron

  • Experimental
    Elecoglipron dose level 2

    Participants will receive elecoglipron at dose level 2, administered orally once daily, in addition to background dapagliflozin 10 mg.

    Drug: Elecoglipron

  • Placebo comparator
    Placebo

    Participants will receive placebo administered orally once daily in addition to background dapagliflozin 10 mg.

    Drug: Placebo

Interventions

  • Elecoglipron is administered orally once daily.

  • DrugPlacebo

    Placebo is administered orally once daily.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline to Week 40

Secondary outcomes

  1. Achievement of HbA1c < 7% (53 mmol/mol)

    Time frame: Week 40

  2. Achievement of HbA1c ≤ 6.5% (48 mmol/mol)

    Time frame: Week 40

  3. Percent change in body weight

    Time frame: Baseline to Week 40

  4. Change from baseline in body weight

    Time frame: Baseline to Week 40

  5. Change from baseline in Systolic Blood Pressure (SBP)

    Time frame: Baseline to Week 40

  6. Achievement of HbA1c < 7% (53 mmol/mol) without hypoglycemia (glucose < 54 mg/dL (3.0 mmol/L) or severe hypoglycemia)

    Time frame: Baseline to Week 40

  7. Change from baseline in Fasting Plasma Glucose (FPG)

    Time frame: Baseline to Week 40

  8. Time to initiation of rescue medication over 40 weeks

    Time frame: Baseline to Week 40

  9. Change from baseline in Diastolic Blood Pressure (DBP)

    Time frame: Baseline to Week 40

07

Study locations

19 of 186 sites recruiting
  • Research Site
    Sun City, Arizona 85373, United States
    Not yet recruiting
  • Research Site
    Surprise, Arizona 85374, United States
    Not yet recruiting
  • Research Site
    Concord, California 94520, United States
    Not yet recruiting
  • Research Site
    Sacramento, California 95821, United States
    Recruiting
  • Research Site
    Victorville, California 92392, United States
    Not yet recruiting
  • Research Site
    Fleming Island, Florida 32003, United States
    Not yet recruiting
  • Research Site
    Lauderdale Lakes, Florida 33313, United States
    Not yet recruiting
  • Research Site
    Leesburg, Florida 34748, United States
    Not yet recruiting
  • Research Site
    Miami Lakes, Florida 33016, United States
    Recruiting
  • Research Site
    Ocoee, Florida 34761, United States
    Recruiting
  • Research Site
    Orlando, Florida 32804, United States
    Not yet recruiting
  • Research Site
    Chicago, Illinois 60640, United States
    Not yet recruiting
  • Research Site
    Braintree, Massachusetts 02184, United States
    Not yet recruiting
  • Research Site
    New Bedford, Massachusetts 02740, United States
    Not yet recruiting
  • Research Site
    Worcester, Massachusetts 01604, United States
    Not yet recruiting
  • Research Site
    Saint Joseph, Michigan 49085, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Saint Paul, Minnesota 55117, United States
    Not yet recruiting
  • Research Site
    Kansas City, Missouri 64112, United States
    Recruiting
  • Research Site
    Omaha, Nebraska 68144, United States
    Not yet recruiting
  • Research Site
    Las Vegas, Nevada 89119, United States
    Not yet recruiting
  • Research Site
    Albuquerque, New Mexico 87102, United States
    Recruiting
  • Research Site
    The Bronx, New York 10451, United States
    Not yet recruiting
  • Research Site
    Kinston, North Carolina 28504, United States
    Not yet recruiting
  • Research Site
    Raleigh, North Carolina 27609, United States
    Recruiting
  • Research Site
    Winston-Salem, North Carolina 27103, United States
    Not yet recruiting
  • Research Site
    Cincinnati, Ohio 45219, United States
    Not yet recruiting
  • Research Site
    East Providence, Rhode Island 02914, United States
    Not yet recruiting
  • Research Site
    Gaffney, South Carolina 29340, United States
    Recruiting
  • Research Site
    Greenville, South Carolina 29605, United States
    Not yet recruiting
  • Research Site
    San Antonio, Texas 78212, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    San Antonio, Texas 78257, United States
    Not yet recruiting
  • Research Site
    Ogden, Utah 84405, United States
    Not yet recruiting
  • Research Site
    Arlington, Virginia 22205, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Dupnitsa, 2600, Bulgaria
    Not yet recruiting
  • Research Site
    Haskovo, 6304, Bulgaria
    Not yet recruiting
  • Research Site
    Kyustendil, 2500, Bulgaria
    Not yet recruiting
  • Research Site
    Pleven, 5801, Bulgaria
    Not yet recruiting
  • Research Site
    Plovdiv, 4002, Bulgaria
    Not yet recruiting
  • Research Site
    Rousse, 7000, Bulgaria
    Not yet recruiting
  • Research Site
    Stara Zagora, 6001, Bulgaria
    Not yet recruiting
  • Research Site
    Varna, 9000, Bulgaria
    Not yet recruiting
  • Research Site
    Varna, 9020, Bulgaria
    Not yet recruiting
  • Research Site
    Binzhou, 256606, China
    Not yet recruiting
  • Research Site
    Changsha, 430033, China
    Not yet recruiting
  • Research Site
    Chengdu, 610081, China
    Not yet recruiting
  • Research Site
    Hangzhou, 310006, China
    Not yet recruiting
  • Research Site
    Jinan, 250013, China
    Not yet recruiting
  • Research Site
    Liaocheng, 252000, China
    Not yet recruiting
  • Research Site
    Liuzhou, 545006, China
    Not yet recruiting
  • Research Site
    Luoyang, 471003, China
    Not yet recruiting
  • Research Site
    Nanjing, 211100, China
    Not yet recruiting
  • Research Site
    Nanyang, 473000, China
    Not yet recruiting
  • Research Site
    Suining Shi, 629000, China
    Not yet recruiting
  • Research Site
    Yibin, 610500, China
    Not yet recruiting
  • Research Site
    Yichang, 443003, China
    Not yet recruiting
  • Research Site
    Zhengzhou, 450002, China
    Not yet recruiting
  • Research Site
    Zhengzhou, 450012, China
    Not yet recruiting
  • Research Site
    Aarhus N, 8200, Denmark
    Not yet recruiting
  • Research Site
    Gistrup, 9260, Denmark
    Not yet recruiting
  • Research Site
    Herlev, 2730, Denmark
    Not yet recruiting
  • Research Site
    Hillerød, 3400, Denmark
    Not yet recruiting
  • Research Site
    Holbæk, 4300, Denmark
    Not yet recruiting
  • Research Site
    Hvidovre, 2650, Denmark
    Not yet recruiting
  • Research Site
    Bad Oeynhausen, 32545, Germany
    Not yet recruiting
  • Research Site
    Berlin, 12047, Germany
    Not yet recruiting
  • Research Site
    Brandenburg an der Havel, 14776, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Chemnitz, 09116, Germany
    Not yet recruiting
  • Research Site
    Duisburg, 47051, Germany
    Not yet recruiting
  • Research Site
    Duisburg, 47269, Germany
    Not yet recruiting
  • Research Site
    Erlangen, 91054, Germany
    Not yet recruiting
  • Research Site
    Frankfurt, 60596, Germany
    Not yet recruiting
  • Research Site
    Hamburg, 22607, Germany
    Not yet recruiting
  • Research Site
    Heilbronn, 74076, Germany
    Not yet recruiting
  • Research Site
    Hohenmölsen, 06679, Germany
    Not yet recruiting
  • Research Site
    Ludwigshafen, 67059, Germany
    Not yet recruiting
  • Research Site
    Münster, 48153, Germany
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Nittendorf, 93152, Germany
    Not yet recruiting
  • Research Site
    Obertshausen, 63179, Germany
    Not yet recruiting
  • Research Site
    Pirna, 01796, Germany
    Not yet recruiting
  • Research Site
    Sankt Ingbert, 66386, Germany
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Stuttgart, 70174, Germany
    Not yet recruiting
  • Research Site
    Aligarh, 202002, India
    Not yet recruiting
  • Research Site
    Belagavi, 590006, India
    Not yet recruiting
  • Research Site
    Belgavi, 590010, India
    Not yet recruiting
  • Research Site
    Calicut, 673 008, India
    Not yet recruiting
  • Research Site
    Chennai, 600037, India
    Not yet recruiting
  • Research Site
    Chennai, 600086, India
    Not yet recruiting
  • Research Site
    Coimbatore, 641018, India
    Not yet recruiting
  • Research Site
    Delhi, 110029, India
    Not yet recruiting
  • Research Site
    Guntur, 522001, India
    Not yet recruiting
  • Research Site
    Kolkata, 700020, India
    Not yet recruiting
  • Research Site
    Lucknow, 226030, India
    Not yet recruiting
  • Research Site
    Nagpur, 440010, India
    Not yet recruiting
  • Research Site
    Pune, 411021, India
    Not yet recruiting
  • Research Site
    Chigasaki-shi, 253-0044, Japan
    Not yet recruiting
  • Research Site
    Chikushino-shi, 8188502, Japan
    Not yet recruiting
  • Research Site
    Gifu, 501-1194, Japan
    Recruiting
  • Research Site
    Kagoshima, 892-0853, Japan
    Not yet recruiting
  • Research Site
    Kitakyushu, 805-8508, Japan
    Not yet recruiting
  • Research Site
    Kumamoto, 862-0965, Japan
    Not yet recruiting

Showing the first 100 of 186 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 24 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2026
First posted
Jun 23, 2026
StartActual
Jul 6, 2026
Primary completionEst.
Jul 13, 2028
CompletionEst.
Jul 13, 2028
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07662135
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 23, 2026
Start date
Jul 6, 2026
Primary completion
Jul 13, 2028 (estimated)
Completion
Jul 13, 2028 (estimated)
Last update
Sep 2, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elecoglipron

Start the discussion